People: Celgene Corp (CELG.O)
CELG.O on Nasdaq
122.58USD
24 May 2013
122.58USD
24 May 2013
Price Change (% chg)
$-1.06 (-0.86%)
$-1.06 (-0.86%)
Prev Close
$123.64
$123.64
Open
$122.61
$122.61
Day's High
$123.71
$123.71
Day's Low
$121.66
$121.66
Volume
2,286,520
2,286,520
Avg. Vol
3,199,165
3,199,165
52-wk High
$131.82
$131.82
52-wk Low
$58.53
$58.53
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Robert Hugin |
57 | 2011 | Chairman of the Board, Chief Executive Officer |
Jacqualyn Fouse |
51 | 2012 | Chief Financial Officer, Executive Vice President |
Perry Karsen |
57 | 2012 | Chief Operating Officer, Executive Vice President |
Mark Alles |
53 | 2012 | Executive Vice President, Chief Commercial Officer |
Thomas Daniel |
58 | 2012 | Executive Vice President, President - Research and Early Development |
Michael Casey |
66 | 2007 | Lead Independent Director |
Richard Barker |
63 | 2012 | Independent Director |
Carrie Cox |
55 | 2009 | Independent Director |
Rodman Drake |
70 | 2006 | Independent Director |
Michael Friedman |
69 | 2011 | Independent Director |
Gilla Kaplan |
65 | 1998 | Independent Director |
James Loughlin |
2007 | Independent Director | |
Ernest Mario |
74 | 2007 | Independent Director |
Biographies
| Name | Description |
|---|---|
Robert Hugin |
Mr. Robert J. Hugin is Chairman of the Board, Chief Executive Officer of Celgene Corp. He was elected as Chairman by the Board of Directors in June 2011, and has served as the Chief Executive Officer since June 16, 2010 and as President since May 1, 2006. He also served as the Chief Operating Officer from May 1, 2006 until June 16, 2010 and Senior Vice President and Chief Financial Officer from June 1999 until May 1, 2006. Mr. Hugin has served as one of the directors since December 2001. Previously, Mr. Hugin had been a Managing Director at J.P. Morgan & Co. Inc., which he joined in 1985. Mr. Hugin received an A.B. degree from Princeton University and an M.B.A. from the University of Virginia. Mr. Hugin is also a director of The Medicines Company, Atlantic Health System, Inc., a non-profit health care system, and Family Promise, a national non-profit network assisting homeless families. |
Jacqualyn Fouse |
Ms. Jacqualyn A. Fouse, Ph.D., is Chief Financial Officer, Executive Vice President of Celgene Corporation since February 15, 2012. She joined the Company in September 2010 as Senior Vice President and Chief Financial Officer. Ms. Fouse assumed the role of Chief Accounting Officer on November 15, 2011. Prior to joining the Company, Ms. Fouse served as Chief Financial Officer of Bunge Limited, a global agribusiness and food company (“Bunge”), since July 2007. Prior to joining Bunge, Ms. Fouse served as Senior Vice President, Chief Financial Officer and Corporate Strategy at Alcon Laboratories, Inc. since 2006, and as its Senior Vice President and Chief Financial Officer since 2002. Ms. Fouse served as Chief Financial Officer from 2001 to 2002 at SAirGroup. Previously, Ms. Fouse held a variety of senior finance positions at Alcon and its then majority owner Nestlé S.A. Ms. Fouse worked at Nestlé from 1993 to 2001, including serving as Group Treasurer of Nestlé from 1999 to 2001. Ms. Fouse worked at Alcon from 1986 to 1993 and held several positions, including Manager Corporate Investments and Domestic Finance. Earlier in her career, she worked at Celanese Chemical and LTV Aerospace and Defense. Ms. Fouse earned a B.A. and an M.A. in Economics and a Ph.D. in Finance from the University of Texas at Arlington. Ms. Fouse also serves as a member of the Board of Directors of Dick’s Sporting Goods. |
Perry Karsen |
Mr. Perry A. Karsen serves as Chief Operating Officer, Executive Vice President of Celgene Corp., since February 15, 2012. He has served as Chief Operations Officer of the Company since July 2010. Mr. Karsen is accountable for all operations functions, including information technology, corporate and business development, quality operations and technical operations. In his capacity as Chief Operations Officer, Mr. Karsen is responsible for the efforts of nearly 25% of the workforce. Mr. Karsen served as President and Chief Executive Officer at Pearl Therapeutics, a privately-held biotechnology company, from February 2009 until July 2010. From 2004 to 2009, Mr. Karsen was Senior Vice President and Head of Worldwide Business Development for us and was also responsible for emerging businesses as President, Asia/Pacific Region. Prior to his tenure with the Company, Mr. Karsen held executive positions at Human Genome Sciences, Bristol-Myers-Squibb, Genentech and Abbott Laboratories. In addition, Mr. Karsen served as a General Partner at Pequot Ventures. Mr. Karsen serves as a member of the Board of Directors of the Biotechnology Industry Organization (BIO); a member of the Board of Directors of BayBio; and a member of the Board of Directors for the Life Sciences Foundation. In addition, Mr. Karsen is a member of the Board of Directors of Agios Pharmaceuticals. Mr. Karsen has a Masters of Management degree from Northwestern University’s Kellogg Graduate School of Management, a Masters in Teaching of Biology from Duke University, and a B.S. in Biological Sciences from the University of Illinois, Urbana. |
Mark Alles |
Mr. Mark J. Alles has been Executive Vice President, Chief Commercial Officer of Celgene Corporation since February 15, 2012. Mr. Alles is responsible for the commercial operations globally. In this capacity, over 40% of the workforce reports to Mr. Alles. He joined the Company in April 2004 and served as Vice President, Global Marketing until March 2009 when he became President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Mr. Alles previously served as Vice President for the U.S. Oncology Business Unit of Aventis Pharmaceuticals and in other commercial sales and marketing management roles over an 11-year period with Aventis. After earning his B.S. degree from Lock Haven University of Pennsylvania and serving as a Captain in the United States Marine Corps, Mr. Alles started his 25-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. He currently serves as a Director for Gilda’s Club NYC, a not-for-profit organization helping people with cancer. |
Thomas Daniel |
Dr. Thomas O. Daniel, M.D., has been Executive Vice President, President - Research and Early Development of Celgene Corp., since February 15, 2012. He has been President, Research and Early Development since December 2006 . He served as the Chief Scientific Officer and Director at Ambrx Inc., a biotechnology company focused on discovering and developing protein-based therapeutics since September 2003. Dr. Daniel served as Vice President, Research at Amgen Inc., where he was Research Site Head of Amgen Washington and Therapeutic Area Head of Inflammation. Prior to Amgen’s acquisition of Immunex, Dr. Daniel served as Senior Vice President of Discovery Research. Dr. Daniel has been a member of the Therapeutic Advisory Board of aTyr Pharma, Inc. since March 1, 2011, and is a director of Ferrumax. A nephrologist and former academic investigator, Dr. Daniel was previously the K.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. He formerly conducted research in the Howard Hughes Medical Institute at UC San Francisco, earned an M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital. |
Michael Casey |
Mr. Michael D. Casey serves as Lead Independent Director of Celgene Corp., since June 2007. He has served as one of Company's Directors since August 2002, is Chairman of the Nominating Committee and a member of the Executive Committee since December 2006 and the Management Compensation and Development Committee (referred to as the Compensation Committee) since April 2006 of Board of Directors. He became independent Lead Director in June 2007. Mr. Casey was a member of the Audit Committee from August 2002 through December 2006. From September 1997 to February 2002, Mr. Casey served as the Chairman, President, Chief Executive Officer and a director of Matrix Pharmaceutical, Inc. From November 1995 to September 1997, Mr. Casey was Executive Vice President at Schein Pharmaceutical, Inc. (or Schein Pharmaceutical). In December 1996, he was appointed President of the retail and specialty products division of Schein Pharmaceutical. From June 1993 to November 1995, he served as President and Chief Operating Officer of Genetic Therapy, Inc. Mr. Casey was President of McNeil Pharmaceutical (a unit of Johnson & Johnson) from 1989 to June 1993 and Vice President, Sales and Marketing for Ortho Pharmaceutical Corp. (a subsidiary of Johnson & Johnson) from 1985 to 1989. Mr. Casey is also a director of Durect Corp. and Abaxis, and served as director of Allos Therapeutics, Inc. through January 2010 and AVI BioPharma through June 2010. |
Richard Barker |
Dr. Richard W. Barker, D.Phil., OBE., has been appointed as an Independent Director and a member of the Audit Committee of Celgene Corporation with effect from January 20, 2012. Dr. Barker was formerly Director General of the Association of the British Pharmaceutical Industry (ABPI), a pharmaceutical industry trade association in the United Kingdom, from 2004 to 2011, and served on the Board and Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and as a Council Member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Dr. Barker is currently director of the Centre for Accelerating Medical Innovations, a member of the Board of iCO Therapeutics, Inc., a Canadian biotech company, Chairman of Stem Cells for Safer Medicine, a public-private partnership using technology to improve drug safety, Founder and Chairman of the Athenaeum Group, an organization devoted to more effective and efficient pharmaceutical research and development among clinicians, industry leaders and regulators, as well as a senior advisor of Aegate, Ltd., an authentication and traceability service for the pharmaceutical industry. |
Carrie Cox |
Ms. Carrie S. Cox has been appointed as an Independent Director of Celgene Corporation effective December 16, 2009 and a member of the Audit Committee since March 2010. Ms. Cox currently serves as the Chief Executive Officer and a member of the board of directors of Humacyte, Inc. Ms. Cox served as Executive Vice President and President of Schering-Plough’s Global Pharmaceutical Business until November 3, 2009 when Schering-Plough merged with Merck & Co., Inc. Prior to joining Schering-Plough, Ms. Cox served as President of Pharmacia Corporation’s pharmaceutical business until its merger with Pfizer Inc. in 2003. Ms. Cox is a member of the Board of Directors of Texas Instruments and has served on their audit and compensation committees, and has recently been appointed to the Board of Directors of Cardinal Health, Inc. Ms. Cox is also a member of the Harvard School of Public Health’s Health Policy and Management Executive Council and a member of the Board of Overseers of the University of Pennsylvania Museum of Archaeology and Anthropology. Ms. Cox is a graduate of the Massachusetts College of Pharmacy. |
Rodman Drake |
Mr. Rodman L. Drake is an Independent Director of Celgene Corp., since April 19, 2006 and is Chairman of the Compensation Committee since June 2007 and a member of the Nominating Committee since April 2006. Since January 2002, Mr. Drake has been Managing Director of Baringo Capital, LLC, a private equity group he co-founded. From November 1997 to January 2002, Mr. Drake was president of Continuation Investments Group Inc., a private equity firm. Prior to that, Mr. Drake was co-chairman of the KMR Power Company and Chief Executive Officer and Managing Director of Cresap McCormick & Paget, a management consulting firm, and served as President of the Mandrake Group, a consulting firm specializing in strategy and organizational design. Mr. Drake is a member of the Board of Directors of The Animal Medical Center of New York. He is also the Chairman of the Brookfield Investment Management Funds and the Columbia Atlantic Fund. Mr. Drake served as a member of the Board of Directors of Jackson Hewitt Tax Service, Inc. from 2004 to 2011. He is. From 2007 to 2009, Mr. Drake served as a member of the Board of Directors of Apex Silver Mines Limited; from 2005 to 2010, he served as a member of the Board of Directors of Student Loan Corporation; and from 2005 to 2010, he served as a member of the Board of Directors of Crystal River Capital, a NYSE listed company which was sold in 2010, where he also served as Chairman, President and CEO from 2009 through 2010. |
Michael Friedman |
Dr. Michael A. Friedman, M.D. has been appointed as an Independent Director of Celgene Corp., since February 2011 and a member of the Nominating Committee since April 2011. Dr. Friedman currently serves as President and Chief Executive Officer of City of Hope, a cancer research, treatment and education institution, as well as Director of the organization’s Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director’s Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman previously served as Deputy Commissioner for the U.S. Food and Drug Administration (FDA), later serving as Acting Commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004, Dr. Friedman has served on the Independent Citizens’ Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of California’s stem cell research effort. Dr. Friedman is a member of the Board of Directors of MannKind Corporation. |
Gilla Kaplan |
Dr. Gilla Kaplan, Ph.D., has been an Independent Director of Celgene Corp., since April 1998 and a member of the Audit Committee. Dr. Kaplan is head of the Laboratory of Mycobacterial Immunity and Pathogenesis at The Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey in Newark, New Jersey, where she was appointed full Member in 2002 and Assistant Director in 2006. Dr. Kaplan also was appointed, in 2005, Professor of Medicine at the University of Medicine and Dentistry of New Jersey. Previously, Dr. Kaplan was an immunologist in the Laboratory at Cellular Physiology and Immunology at The Rockefeller University in New York where she was an Associate Professor. |
James Loughlin |
Mr. James J. Loughlin is an Independent Director of Celgene Corp., since January 8, 2007 and is Chairman of the Audit Committee since June 2008 and a member of the Compensation Committee since June 2008. Mr. Loughlin served as the National Director of the Pharmaceuticals Practice at KPMG LLP (or KPMG), and a five-year term as member of the Board of Directors of KPMG. Additionally, Mr. Loughlin served as Chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. He also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees. In addition, Mr. Loughlin served as a member of the Board of Directors of Alfacell Corporation (until 2008) and Datascope Corp. (until January 2009). |
Ernest Mario |
Dr. Ernest Mario, Ph.D., has been appointed as an Independent Director of Celgene Corp., since August 22, 2007 and is a member of the Nominating Committee since August 2007 and the Executive Committee since June 2008. Dr. Mario is a former Deputy Chairman and Chief Executive of Glaxo Holdings plc and a former Chairman and Chief Executive Officer of ALZA Corporation. Dr. Mario has been a Director of Boston Scientific since October 2001 and currently is the Lead Director of Pharmaceutical Product Development, Inc. From 2003 to 2007, he was Chairman and Chief Executive of Reliant Pharmaceuticals, Inc. Dr. Mario currently is the Chief Executive Officer and Chairman of Capnia, Inc., a privately held specialty pharmaceutical company in Palo Alto, CA. He is Chairman of the American Foundation for Pharmaceutical Education and serves as an advisor to the pharmacy schools at the University of Rhode Island and The Ernest Mario School of Pharmacy at Rutgers University. Dr. Mario is the recipient of the 2007 Remington Honor Medal, which is the highest recognition given by the American Pharmacists Association. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Robert Hugin |
8,918,000 |
Jacqualyn Fouse |
2,535,030 |
Perry Karsen |
-- |
Mark Alles |
-- |
Thomas Daniel |
-- |
Michael Casey |
-- |
Richard Barker |
-- |
Carrie Cox |
-- |
Rodman Drake |
-- |
Michael Friedman |
-- |
Gilla Kaplan |
-- |
James Loughlin |
-- |
Ernest Mario |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Robert Hugin |
3,046,953 | 61,551,300 |
Jacqualyn Fouse |
152,982 | 5,151,540 |
Perry Karsen |
0 | 0 |
Mark Alles |
0 | 0 |
Thomas Daniel |
0 | 0 |
Michael Casey |
0 | 0 |
Richard Barker |
0 | 0 |
Carrie Cox |
0 | 0 |
Rodman Drake |
0 | 0 |
Michael Friedman |
0 | 0 |
Gilla Kaplan |
0 | 0 |
James Loughlin |
0 | 0 |
Ernest Mario |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
CASEY MICHAEL D |
9,294 | $0.00 |
CASEY MICHAEL D |
9,294 | $11.21 |
CASEY MICHAEL D |
9,294 | $118.07 |
CASEY MICHAEL D |
5,706 | $0.00 |
CASEY MICHAEL D |
5,706 | $120.11 |
DRAKE RODMAN L |
1,000 | $38.43 |
CASEY MICHAEL D |
5,706 | $11.21 |
HUGIN ROBERT J |
16,700 | $0.00 |
DANIEL THOMAS O |
4,583 | $0.00 |
DANIEL THOMAS O |
2,225 | $123.00 |
ALLES MARK J |
4,583 | $0.00 |
ALLES MARK J |
1,791 | $123.00 |
HUGIN ROBERT J |
8,658 | $123.00 |
DRAKE RODMAN L |
200 | $98.30 |
DRAKE RODMAN L |
200 | $98.70 |
HUGIN ROBERT J |
7,500 | $0.00 |
HUGIN ROBERT J |
12,821 | $80.03 |
HUGIN ROBERT J |
20,172 | $25.68 |
KAPLAN GILLA |
48,000 | $8.41 |
KAPLAN GILLA |
32,400 | $81.42 |
DRAKE RODMAN L |
1,000 | $38.43 |
HUGIN ROBERT J |
7,000 | $0.00 |
CASEY MICHAEL D |
12,000 | $11.28 |
LOUGHLIN JAMES J |
600 | $60.29 |
DRAKE RODMAN L |
685 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
